FDA Approves DAPAGLIFLOZIN — Ajanta Pharma USA Inc.

# FDA Approves Generic Dapagliflozin from Ajanta Pharma USA The U.S. FDA has approved Ajanta Pharma USA Inc.'s generic version of dapagliflozin, an SGLT2 inhibitor used to treat type 2 diabetes and heart failure, potentially intensifying competition in the oral antidiabetic market and putting pricing pressure on the branded Farxiga formulation. This approval is expected to expand patient access to the medication while reducing treatment costs for payers and consumers in a highly competitive therapeutic segment.